Comparative Genome Sequencing of Canine Distemper Virus Across Different Continents and Lineages, using Nanopore Technology

Methods: A Markov model that follows a cohort from 0 to 7 years of age was developed to simulate the natural history of rotavirus disease.The model was used to evaluate three different scenarios-i) vaccination with RotaTeq; ii) vaccination with LLR3; iii) no-vaccination to estimate the number of rotavirus-related cases.The model was parameterized using published information on rotavirus epidemiology, up-to-date RotaTeq effectiveness and LLR3 efficacy in China, and incidence of 11,996/10 0,0 0 0 among children in China as abstracted from national estimates and the peer-reviewed literature.Based on the natural history of rotavirus disease, the model considered that individuals could have up to five rotavirus infections, the first two being the ones that could lead to hospitalization.Due to limited clinical evidence for the newly available LLR3, two different vaccine waning profiles based on locally existing products (LLR and RotaTeq) were used to estimate the impact of LLR3.We considered high (90%) and low (50%) vaccination coverage scenarios (since rotavirus vaccines are in the private market).Results/Discussion: For a cohort of 10 0,0 0 0 children over the first 7 years of life, and in the absence of a rotavirus vaccine in China, 64,746 symptomatic rotavirus cases, 11,708 outpatient visits and 899 hospitalizations are expected.Using RotaTeq, 86%(49%) of rotavirus symptomatic cases and outpatient visits, and 85%(49%) of hospitalizations can be averted compared to no vaccination under the high(low) vaccination coverage scenario.Using LLR3, under the LLR waning profile assumption, would avert 40%(23%) of rotavirus symptomatic cases and outpatient visits, and 50%(29%) hospitalizations compared to no vaccination, in the high(low) vaccination coverage scenario.Using LLR3 (with assumed RotaTeq waning profile), would avert 48%(28%) of rotavirus symptomatic cases and outpatient visits, and 61%(35%) hospitalizations compared to no vaccination, in the high(low) vaccination coverage scenario.Conclusion: Widespread use of rotavirus vaccines can avert a significant number of RVGE outcomes, with close to two times higher potential public health impact for RotaTeq compared with LLR3.